AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

Commerce Commission approves Huntly agreement
Markets

Commerce Commission approves Huntly agreement

Gentailer deal to keep Rankine unit running gets a quick tick.

The market just wobbled. Will it fall down?
Markets Opinion

The market just wobbled. Will it fall down?

Recent losses can be explained by one word: speculation.

RBNZ says risks linked to new mortgage lending contained
Economy

RBNZ says risks linked to new mortgage lending contained

House prices near the top of RBNZ's range of sustainable estimates.

Inside ACC's $180m small cap strategy
Markets

Inside ACC's $180m small cap strategy

In one $1 billion portfolio, it's the small caps driving performance.